AstraZeneca PLC ADR
AZN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$56.00 | Lcp | Sydsgtngc |
AstraZeneca Remains Well Positioned for Strong Growth Based on a Broad Drug Portfolio
Business Strategy and Outlook
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The replenishment of new drugs is setting up industry-leading growth.